Three West Coast healthcare venture capital firms – Canaan Partners, Vivo Capital and Frazier Healthcare – are teaming up to launch a stealth new startup called Nexcida Therapeutics. It’s focused on infectious disease therapeutics, CEO David Socks said in an email.
The startup was launched by Frazier Healthcare, which also led the Series A, with Vivo and Canaan investing as well. Socks is an alum from Cadence Pharmaceuticals and Incline Therapeutics, is the startup’s CEO.
It’s raised $2.75 million of a proposed $21.3 million round, according to a regulatory filing. Nexcida is in its nascence and under the radar – it has no website.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Canaan and Frazier Healthcare are your typical life sciences VCs; Vivo Capital, however, focuses on building companies both stateside and in China.
Photo: Flickr user Fun Flying